Zydus Cadila gets USFDA nod for skin ointment, stomach ailment drug
Zydus Cadila has received final approval from the US health regulator to market Nystatin ointment and Omeprazoleand Sodium Bicarbonate capsules. Nys28-05-2018
28-05-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Nystatin Ointment USP and Omeprazole and Sodium Bicarbonate Capsules28-05-2018
Cadila Healthcare launch pipeline points to healthy outlook, stock gains
Strong Q4, healthy forecast could result in more upside for stock26-05-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Cadila's Net Profit up by 53% in Q425-05-2018
Board Meeting-Outcome of Board Meeting
Pursuant to the SEBI Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016, we hereby give a declaration that the Statutory Auditors-M/s. Deloitte Haskins & Sells LLP [Firm Registration No. 117366W/W-100018], Chartered Accountants have submitted their Audit Reports for the year ended on March 31, 2018 with an unmodified opinion.25-05-2018
Board Meeting-Outcome of Board Meeting
We hereby inform that the Board of Directors at their meeting held today considered and approved in-principle, the following fund raising proposals, which are subject to approval of the members at the ensuing Annual General Meeting: (i) to raise funds by issue of Equity Shares / convertible Bonds / Debentures through Qualified Institutional Placement [QIP] / GDR / ADR, for an aggregate amount up to Rs. 10,000 crores,...25-05-2018
Board Meeting-Outcome of Board Meeting
The Board of Directors at the meeting held today i.e. May 25, 2018 decided to publish only consolidated financial results in the newspapers for the Financial Year 2018-2019. In view of it, as required under Regulation No. 33[3] of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015, we hereby inform that the Company shall publish only consolidated financial results in the newspapers for the Financial Year 2018-2019.25-05-2018
Corporate Action-Board approves Dividend
Annual General Meeting of the Company is scheduled to be held on August 13, 2018.25-05-2018
Corporate Action-Board approves Dividend
The Board of Directors at their meeting held today have recommended final dividend of Rs. 3.50/- (350%) per equity share of Re. 1/- each, subject to approval of the shareholders at the ensuing Annual General Meeting scheduled to be held on August 13, 2018.25-05-2018